# Greenland Mines Ltd.

**GRMLW**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001907223


# None

### No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $9.6M |
| **Warnings** | late filer, thin data<br>not computable: dilution, degenerate inputs, distress, fortress balance sheet |
| **Inputs computable** | 3 of 14 |
| **Graded from** | filings received through Aug 14, 2026<br>83 days before the rescan; latest periodic filing 10-Q received Aug 17, 2026 |
| **Last close** | $0.36<br>2026-10-30; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Apr 1, 2026*

Mines"), formerly known as Klotho Neurosciences, Inc., develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative On September 12, 2022, the Company acquired five market-approved anti-cancer drugs approved for sale in Germany.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 5.2** | | | | | | |
| Gross profitability | not computable | 32.4% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | |
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (77.4%) | (6.6%) | 5.2 | 801 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 0.1** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | |
| Altman Z double-prime | 69.33 | (0.35) | 0.1 | 746 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | not computable | 2.92x | | | |
| *current liabilities must exceed $100,000* | | | | | |
| **Growth and financing, sleeve percentile 98.9** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 0* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *four consecutive annual FCF observations are required; found 0* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | (56.7%) | 2.2% | 98.9 | 696 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Late filer | found 5 NT 10-K/Q filings in the last eight quarters |
| Thin data | 3 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-10-30 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 358.2% | (2.2%) | 99 |
| Distance from 52-week high | (68.6%) | (26.8%) | 13 |
| EBIT to enterprise value | not computable | (1.4%) | |
| Free cash flow yield | not computable | (0.9%) | |
| Book value to price | not computable | 0.27 | |
| Sales to price | not computable | 0.28 | |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | 1.35 | (0.19) | 99 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $9.3M |
| Operating cash flow, four quarters | -$14.2M |
| Months of runway | 7.8 |
| Days since last periodic filing | 80 (10-Q received Aug 17, 2026) |
| Median daily dollar volume, 63 sessions | $10,345 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$10.6M | 2025-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$5.9M | 2025-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 3 | assets | us-gaap:Assets | $9.6M | 2025-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 4 | assets | us-gaap:Assets | $2.5M | 2024-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 5 | current assets | us-gaap:AssetsCurrent | $7.3M | 2025-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $76,764 | 2025-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$21.1M | 2025-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$7.1M | 2025-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 9 | book equity | us-gaap:StockholdersEquity | $9.5M | 2025-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 10 | liabilities | us-gaap:Liabilities | $129,764 | 2025-12-31 | 2026-08-14 | 10-K/A | 26-090213 |
| 11 | assets | us-gaap:Assets | $2.2M | 2023-12-31 | 2025-03-31 | 10-K | 25-026372 |
| 12 | assets | us-gaap:Assets | $118.2M | 2022-12-31 | 2024-04-17 | 10-K | 24-033573 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.